Browse > Article
http://dx.doi.org/10.9708/jksci.2020.25.10.115

Root bark extract of Cudrania tricuspidata reduces LPS-induced inflammation in macrophages of atherogenic mice  

Lee, Mi-Ran (Dept. of Biomedical Laboratory Science, Jungwon University)
Publication Information
Journal of the Korea Society of Computer and Information / v.25, no.10, 2020 , pp. 115-123 More about this Journal
Abstract
In this paper, we propose to evaluate the potential anti-inflammatory properties of root bark extract of Cudrania (C.) tricuspidata on lipopolysaccharide (LPS)-induced inflammation in macrophages of apolipoprotein E (ApoE) knockout (ApoE-/-) mice, murine model of atherosclerosis. Atherosclerosis is a chronic vascular inflammatory disease. C. tricuspidata is a small tree of the Moraceae family and its extract has anti-inflammatory activities. However, its role in the progress of atherosclerosis is not yet clear. To determine anti-inflammatory effects of C. tricuspidata in atherogenesis, we applied LPS in peritoneal macrophages of ApoE-/- mice and measured cell viability by CCK-8 and expression of pro-inflammatory cytokines by qRT-PCR following treatment with root bark extract of C. tricuspidata. Research data was expressed as differences between the cells treated with LPS and root bark extract and the cells treated with LPS alone (control) by a two-tailed non-parametric Mann-Whitney U-test using GraphPad Instat program. No cytotoxic effect was observed when the cells were treated with the extract at concentrations ≤ 100 ㎍/mL. The expression of inflammatory cytokines, including MCP-1, IL-1β, IFN-γ, TNF-α, and IL-6 were inhibited by the extract. These results indicated that the extract has an anti-inflammatory effect and therefore a possible role in the treatment of atherosclerosis.
Keywords
Cudrania tricuspidata; Lipopolysaccharide; Inflammation; Peritoneal macrophage; Atherosclerosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Zaman S, Goldberger JJ, Kovoor P., "Sudden Death Risk-Stratifi cation in 2018-2019: The Old and the New" Heart Lung Circ. Vol. 28, No. 1, pp. 57-64, Jan 2019. DOI: 10.1016/j.hlc.2018.08.027   DOI
2 Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013", Lancet. Vol. 385, No. 9963, pp. 117-171, Jan 2015. DOI: 10.1016/S0140-6736(14)61682-2   DOI
3 Statistics Korea. 2019. Cause-of-death statistics in 2019 pp. 1-56
4 Gallino A, Aboyans V, Diehm C, et al. "Non-coronary atherosclerosis", Eur Heart J. Vol. 35, No. 17, pp. 1112-1119, May 2014. DOI: 10.1093/eurheartj/ehu071   DOI
5 Gimbrone MA Jr, Garcia-Cardena G. "Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis", Circ Res. Vol. 118, No. 4, pp. 620-636, Feb 2016. DOI: 10.1161/CIRCRESAHA.115.306301   DOI
6 Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD., "Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation", Oxid Med Cell Longev. Vol. 2019, pp. 8563845, July 2019. DOI: 10.1155/2019/8563845
7 Ridker, P.M. "Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin", Eur. Heart J. Vol. 37, No. 22, pp. 1720-1722, Feb 2016. DOI: 10.1093/eurheartj/ehw024   DOI
8 Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. "Mechanisms of foam cell formation in atherosclerosis", J Mol Med (Berl). Vol. 95, No. 11, pp. 1153-1165, Nov 2017. DOI: 10.1007/s00109-017-1575-8   DOI
9 Malekmohammad K, Sewell RD, Rafieian-Kopaei M, "Antioxidants and Atherosclerosis: Mechanistic Aspects", Biomolecules. Vol. 9, No. 8, pp.301, July 2019. DOI: 10.3390/biom9080301   DOI
10 Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. "Cholesterol Treatment Trialists'(CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials", Lancet. Vol. 380, No. 9841, pp. 581-590. May 2012. DOI: 10.1016/S0140-6736(12)60367-5   DOI
11 Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med. Vol. 359, No. 21, pp. 2195-2207, Nov 2008. DOI: 10.1056/NEJMoa0807646   DOI
12 Guyton JR, Bays HE, Grundy SM, et al. "An assessment by the statin intolerance panel", J Clin Lipidol. Vol. 8, No. 3, pp. S72-81, May 2014. DOI: 10.1016/j.jacl.2014.03.002   DOI
13 Sung J, Kim SH, Song HR, et al. "Lipid-lowering treatment practice patterns in Korea: comparison with the data obtained from the CEPHEUS pan-Asian study", J Atherocler Thromb. Vol. 21, No. 11, pp. 1219-1227, July 2014. DOI: 10.5551/jat.23242   DOI
14 Park KH., Park YD., Han JM. Im KR., Lee BW., et al. "Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata", Bioorg Med Chem Lett. Vol. 16, No. 21, pp. 5580-5583, Nov 2006. DOI: 10.1016/j.bmcl.2006.08.032   DOI
15 Li X, Yao Z, Jiang X, Sun J, Ran G, et al. "Bioactive compounds from Cudrania tricuspidata: A natural anticancer source", Crit Rev Food Sci Nutr. Vol. 60, No. 3, pp. 494-514. Dec 2020. DOI: 10.1080/10408398.2018.1541866   DOI
16 Fujimoto T, Hano Y, Nomura T. "Components of Root Bark of Cudrania tricuspidata l.1,2 Structures of Four New Isoprenylated Xanthones, Cudraxanthones A, B, C and D", Planta Med. Vol. 50, No. 3, pp. 218-221, June 1984. DOI: 10.1055/s-2007-969682   DOI
17 Kim OK., Nam DE., Jun W., Lee J. "Anti-wrinkle Activity of a Curdrania tricuspidata Extract on Ultraviolet-induced Photoaging", J Korean Soc Food Sci Nutr. Vol. 42, No. 4, pp. 608-614, June 2013. DOI: 10.3746/jkfn.2013.42.4.608   DOI
18 Lee T, Kwon J, Lee D, Mar W. "Effects of Cudrania tricuspidata Fruit Extract and Its Active Compound, 5,7,3',4'-Tetrahydroxy-6, 8-diprenylisoflavone, on the High- Affinity IgE Receptor-Media ted Activation of Syk in Mast Cells", J Agric Food Chem. Vol. 63, No. 22, pp. 5459-5467, June 2015. DOI: 10.1021/acs.jafc.5b00903   DOI
19 Robert M., Merel L., Roger R., Douwe D,, Erik S., et al. "PCSK9 inhibitors in clinical practice: Delivering on the promise?", Atherosclerosis. Vol. 270, pp. 205-210, Mar 2018. DOI: 10.1016/j.atherosclerosis.2017.11.027   DOI
20 Xin LT., Yue SJ., Fan YC., Wu JS., Yan D., Guan HS, et al. "Cudrania tricuspidata: an updated review on ethnomedicine, phytochemistry and pharmacology", RSC Adv. Vol. 7, No. 51, pp. 31807-31832, Dec 2017. DOI: org/10.1039/C7RA04322H   DOI
21 Jo YH., Kim SB., Liu Q., Hwang BY., Lee MK. "Prenylated xanthones from the roots of Cudrania tricuspidata as inhibitors of lipopolysaccharide-stimulated nitric oxide production" Arch Pharm. Vol. 350, No. 1, pp. e1600263, Jan 2017. DOI: 10.1002/ardp.201600263   DOI
22 Cho SS., Yang JH., Seo KH., Shin SM., Park EY., Cho SS, et al. "Cudrania tricuspidata extract and its major constituents inhibit oxidative stress-induced liver injury" J Med Food. Vol. 22, No. 6, pp. 602-613, June 2019. DOI: 10.1089/jmf.2018.4322   DOI
23 Jiang X, Cao C, Sun W, Chen Z, Li X, et al. "Scandenolone from Cudrania tricuspidata fruit extract suppresses the viability of breast cancer cells (MCF-7) in vitro and in vivo", Food Chem Toxicol. Vol. 126, pp. 56-66, Feb 2019. DOI: 10.1016/j.fct.2019.02.020   DOI
24 Jo YH., Kim SB., Ahn JH., Turk A., Kwon EB., Kim MO, et al. "Xanthones from the stems of Cudrania tricuspidata and their inhibitory effects on pancreatic lipase and fat accumulation. Bioorg Chem. Vol. 92, pp. 103234, Nov 2019. DOI: 10.1016/j.bioorg.2019.103234   DOI
25 Cheng N, Liang Y, Du X, Ye RD. "Serum amyloid A promotes LPS clearance and suppresses LPS-induced inflammation and tissue injury ," EMBO Rep. Vol. 19 No. 10, pp. e45517, Oct 2018. DOI: 10.15252/embr.201745517
26 Lin J, Kakkar V, Lu X. "Impact of MCP-1 in atherosclerosis", Curr Pharm Des. Vol. 20, No. 28, pp.4580-4588, Jan 2014. DOI: 10.2174/1381612820666140522115801   DOI
27 D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A. & Clark, G. C. Targeting the "cytokine storm" for therapeutic benefit. Clin. Vaccine Immunol. Vol. 20, No. 3 pp. 319-327, Jan 2013. DOI: 10.1128/CVI.00636-12   DOI
28 Lee SB, Shin JS, Han HS, Lee HH, Park JC, et al. "Kaempferol 7-O-$\beta$-D-glucoside isolated from the leaves of Cudrania tricuspidata inhibits LPS-induced expression of pro-inflammatory mediators through inactivation of $NF-{\kappa}B$, AP-1, and JAK-STAT in RAW 264.7 macrophages", Chem Biol Interact. Vol. 284, pp. 101-111, Mar 2018. DOI: 10.1016/j.cbi.2018.02.022   DOI
29 Bartekova M,, Radosinska J, Jelemensky M, Dhalla SD. "Role of cytokines and inflammation in heart function during health and disease" Heart Fail Rev. Vol. 23, No. 5, pp. 733-758, Sep 2018. DOI: 10.1007/s10741-018-9716-x   DOI
30 Hartman J, Frishman WH. "Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy", Cardiol Rev. Vol. 22, No. 3, pp. 147-151, May-June 2014. DOI: 10.1097/CRD.0000000000000021   DOI
31 Park JG and Oh GT. "Current pharmacotherapies for atherosclerotic cardiovascular diseases", BMB Rep. Vol. 44. No. 8, pp. 497-505, Aug 2011. DOI: 10.5483/bmbrep.2011.44.8.497   DOI
32 Koh BS, Park HJ, Kim SR, Monn IJ, Leem D, et al. "Adverse drug reactions after taking the extract of Cudrania tricuspidata", Allergy Asthma Respir Dis. Vol. 2, No. 5, pp. 387-390, Jan 2014. DOI: 10.4168/aard.2014.2.5.387   DOI
33 Chang SL, Huang YH, Yang CH, Hu S, Hong HS. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol Vol. 88, pp. 363-365, Jan 2008. DOI: 10.2340/00015555-0438   DOI